AVTE vs. AVBP, LYEL, IGMS, OLMA, GHRS, STOK, CALT, CMPS, OCS, and PHAT
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include ArriVent BioPharma (AVBP), Lyell Immunopharma (LYEL), IGM Biosciences (IGMS), Olema Pharmaceuticals (OLMA), GH Research (GHRS), Stoke Therapeutics (STOK), Calliditas Therapeutics AB (publ) (CALT), COMPASS Pathways (CMPS), Oculis (OCS), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Aerovate Therapeutics presently has a consensus target price of $49.33, indicating a potential upside of 138.21%. ArriVent BioPharma has a consensus target price of $29.25, indicating a potential upside of 67.24%. Given Aerovate Therapeutics' higher possible upside, analysts plainly believe Aerovate Therapeutics is more favorable than ArriVent BioPharma.
ArriVent BioPharma's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.
9.5% of ArriVent BioPharma shares are held by institutional investors. 19.3% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, ArriVent BioPharma had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for ArriVent BioPharma and 5 mentions for Aerovate Therapeutics. ArriVent BioPharma's average media sentiment score of 0.60 beat Aerovate Therapeutics' score of 0.14 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
Aerovate Therapeutics received 10 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
Summary
ArriVent BioPharma beats Aerovate Therapeutics on 8 of the 11 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
